百濟神州(06160.HK)於2023年ASCO年會上公佈管線進展,繼續強化其抗腫瘤藥物組合的優勢
格隆匯5月29日丨百濟神州(06160.HK)發佈公吿,百濟神州於2023年5月25日(美國東部時間)宣佈將於芝加哥舉行的2023年美國臨牀腫瘤學會(ASCO)年會上公佈其研發管線的最新數據,以展示其作為業內規模最大的藥物研發團隊之一的研究實力及研發成果。即將公佈的進展包括百濟神州核心產品澤布替尼(中文商品名:百悦澤®)與替雷利珠單抗(中文商品名:百澤安®)的臨牀數據,以及其OX40激動劑和BCL-2 抑制劑的早期研究結果。
百濟神州高級副總裁、全球研發負責人汪來博士表示:“我們將於ASCO年會上展示的數據證明了百濟神州腫瘤學藥物組合的優勢,我們的BCL-2抑制劑和OX40激動劑早期數據支持差異化的生物學假設,創新藥物澤布替尼和替雷利珠單抗在單藥治療和聯合用藥的全球開發計劃中也持續不斷地產生新的研究數據。在百濟神州,我們始終以患者為先,持續推進包含潛在同類最佳與同類首創藥物研發管線的開發。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.